Nothing Special   »   [go: up one dir, main page]

DE602004021904D1 - Gyraseinhibitoren und deren verwendungen - Google Patents

Gyraseinhibitoren und deren verwendungen

Info

Publication number
DE602004021904D1
DE602004021904D1 DE602004021904T DE602004021904T DE602004021904D1 DE 602004021904 D1 DE602004021904 D1 DE 602004021904D1 DE 602004021904 T DE602004021904 T DE 602004021904T DE 602004021904 T DE602004021904 T DE 602004021904T DE 602004021904 D1 DE602004021904 D1 DE 602004021904D1
Authority
DE
Germany
Prior art keywords
gyraseinhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004021904T
Other languages
English (en)
Inventor
Paul S Charifson
David D Deininger
Anne-Laure Grillot
Yusheng Liao
Steven M Ronkin
Dean Stamos
Emauele Perola
Tiansheng Wang
Tiran Arnaud Le
Joseph Drumm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of DE602004021904D1 publication Critical patent/DE602004021904D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE602004021904T 2003-01-31 2004-01-29 Gyraseinhibitoren und deren verwendungen Expired - Lifetime DE602004021904D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44391703P 2003-01-31 2003-01-31
PCT/US2004/002541 WO2005012292A1 (en) 2003-01-31 2004-01-29 Gyrase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
DE602004021904D1 true DE602004021904D1 (de) 2009-08-20

Family

ID=34115255

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004021904T Expired - Lifetime DE602004021904D1 (de) 2003-01-31 2004-01-29 Gyraseinhibitoren und deren verwendungen

Country Status (25)

Country Link
US (3) US7495014B2 (de)
EP (1) EP1592686B1 (de)
JP (2) JP4691033B2 (de)
KR (1) KR20060056270A (de)
CN (1) CN100393714C (de)
AR (1) AR042956A1 (de)
AT (1) ATE435859T1 (de)
AU (1) AU2004261545B2 (de)
CA (1) CA2513463C (de)
CY (1) CY1109385T1 (de)
DE (1) DE602004021904D1 (de)
DK (1) DK1592686T3 (de)
ES (1) ES2327642T3 (de)
HK (1) HK1087699A1 (de)
IL (1) IL169720A (de)
MX (1) MXPA05008126A (de)
MY (1) MY139124A (de)
NO (1) NO20053845L (de)
NZ (1) NZ541885A (de)
PT (1) PT1592686E (de)
RU (1) RU2350612C2 (de)
SI (1) SI1592686T1 (de)
TW (1) TWI334416B (de)
WO (1) WO2005012292A1 (de)
ZA (1) ZA200505773B (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727992B2 (en) * 2002-06-13 2010-06-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US8404852B2 (en) 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8193352B2 (en) 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) * 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
WO2006025978A2 (en) * 2004-07-23 2006-03-09 University Of Medicine And Dentistry Of New Jersey Non-antibiotic intervention of chlamydial infection
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
DE102005028862A1 (de) * 2005-06-22 2007-01-11 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
CN101321744A (zh) * 2005-11-07 2008-12-10 沃泰克斯药物股份有限公司 作为回旋酶抑制剂的苯并咪唑衍生物
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
GB0612428D0 (en) * 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
GB0724349D0 (en) * 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
WO2009001915A1 (ja) * 2007-06-28 2008-12-31 Takeda Pharmaceutical Company Limited 置換イミダゾール化合物およびその用途
WO2009027733A1 (en) * 2007-08-24 2009-03-05 Astrazeneca Ab (2-pyridin-3-ylimidazo[1,2-b]pyridazin-6-yl) urea derivatives as antibacterial agents
TW200940527A (en) * 2007-12-07 2009-10-01 Vertex Pharma Solid forms of 1-ethyl-3-(5-(5-fluoropyridin-3-yl)-7-(pyrimidin-2-yl)-1H-benzo[d]imidazol-2-yl)urea
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
CA2710194C (en) * 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
TW200940537A (en) * 2008-02-26 2009-10-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
AU2009254930A1 (en) 2008-06-04 2009-12-10 Astrazeneca Ab Heterocyclic urea derivatives for the treatment of bacterial infections
EP2321309A1 (de) * 2008-06-25 2011-05-18 Ranbaxy Laboratories Limited Benzothiazole und azaanaloga davon zur verwendung als antibakterielle mittel
ES2422718T3 (es) * 2009-04-02 2013-09-13 Merck Patent Gmbh Derivados de piperidina y piperazina como inhibidores de la autotaxina
WO2011028492A2 (en) * 2009-08-24 2011-03-10 The Regents Of The University Of California Sortase a inhibitors
US20110120915A1 (en) * 2009-11-24 2011-05-26 Chevron U.S.A. Inc. Hydrogenation of solid carbonaceous materials using mixed catalysts
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US20150174137A1 (en) * 2010-06-02 2015-06-25 Alcon Research, Ltd. Compositions for treating microbial infections
MX341342B (es) * 2011-01-14 2016-08-17 Vertex Pharma Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.
EP2663557B1 (de) 2011-01-14 2015-05-27 Vertex Pharmaceuticals Incorporated Pyrimidingyrase- und topoisomerase-iv-hemmer
SG191945A1 (en) 2011-01-14 2013-08-30 Vertex Pharma Process of making gyrase and topoisomerase iv inhibitors
CN103384666A (zh) * 2011-01-14 2013-11-06 沃泰克斯药物股份有限公司 固体形式的促旋酶抑制剂（r）-1-乙基-3-[5-[2-（1-羟基-1-甲基-乙基）嘧啶-5-基]-7-（四氢呋喃-2-基）-1氢-苯并咪唑-2-基]脲
JP5977344B2 (ja) * 2011-06-20 2016-08-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ジャイレースおよびトポイソメラーゼ阻害剤のリン酸エステル
US9572809B2 (en) 2012-07-18 2017-02-21 Spero Trinem, Inc. Combination therapy to treat Mycobacterium diseases
WO2014015105A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9636328B2 (en) 2013-06-21 2017-05-02 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
CA3190653A1 (en) * 2013-06-21 2015-01-08 Zenith Epigenetics Ltd. Bicyclic bromodomain inhibitors
CA2919948C (en) 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
US20170007615A1 (en) 2014-02-03 2017-01-12 Biota Europe Ltd Antibacterial Compounds
EP2913330A1 (de) * 2014-02-27 2015-09-02 Laboratoire Biodim Als Arzneimittel geeignete kondensierte Derivate von Imidazol
MX2016012808A (es) 2014-04-02 2017-01-05 Intermune Inc Piridinonas anti-fibroticas.
EP3227281A4 (de) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituierte pyridinone als bromodomain-inhibitoren
JP2017537946A (ja) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての置換複素環
JP2017538721A (ja) 2014-12-17 2017-12-28 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメインの阻害剤
CN105884752B (zh) * 2015-02-13 2018-08-31 山东轩竹医药科技有限公司 并环类回旋酶和拓扑异构酶iv抑制剂
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
CN106167486B (zh) * 2015-05-22 2019-06-14 北京四环制药有限公司 单环类回旋酶和拓扑异构酶iv抑制剂
EP3316969B1 (de) 2015-07-02 2022-03-02 Janssen Sciences Ireland Unlimited Company Antibakterielle verbindungen
CN109476657A (zh) 2016-06-16 2019-03-15 爱尔兰詹森科学公司 作为抗细菌剂的杂环化合物
PT3475272T (pt) 2016-06-24 2023-12-15 Univ California Derivados de ftalazina como inibidores de parp1, parp2 e/ou tubulina úteis para o tratamento do cancro
MA47676A (fr) 2017-03-01 2021-06-02 Janssen Sciences Ireland Unlimited Co Polythérapie
JPWO2018174288A1 (ja) 2017-03-24 2020-01-23 大正製薬株式会社 ２（１ｈ）−キノリノン誘導体
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
EP4077310B1 (de) * 2019-12-19 2024-05-01 Université de Strasbourg Sigma-1-rezeptorliganden und verwendungen davon
KR20230169573A (ko) * 2022-06-09 2023-12-18 한국화학연구원 벤즈이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 또는 감염증의 예방 또는 치료용 약학적 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2015676A1 (de) * 1970-04-02 1971-10-21 Farbenfabriken Bayer Ag, 5090 Leverkusen Neue Imine der 2-Formyl-chinoxalindi-N-oxidcarbon-säure-(3) und deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als antimikrobielle Mittel
US4174400A (en) 1978-09-13 1979-11-13 Merck & Co., Inc. Anthelmintic benzimidazoles
US4512998A (en) 1980-10-20 1985-04-23 Schering Corporation Anthelmintic benzimidazole carbamates
CA2028530A1 (en) 1989-11-21 1991-05-22 Christian Hubschwerlen Substituted pyrimidobenzimidazole derivatives
ATE155143T1 (de) * 1991-09-27 1997-07-15 Merrell Pharma Inc 2-substituierte indan-2-mercaptoacetylamid- verbindungen mit enkephalinase und ace- hemmwirkung
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
TW538046B (en) 1998-01-08 2003-06-21 Hoechst Marion Roussel Inc Aromatic amides having antiobiotic activities and the preparation processes, intermediates and pharmaceutical composition thereof
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
GB9911594D0 (en) 1999-05-19 1999-07-21 Smithkline Beecham Plc Novel compounds
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
WO2002060879A2 (en) * 2000-12-15 2002-08-08 Vertex Pharmaceuticals Incorporated Bacterial gyrase inhibitors and uses thereof
US7727992B2 (en) 2002-06-13 2010-06-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8193352B2 (en) 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7618974B2 (en) * 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7582641B2 (en) * 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
CN101321744A (zh) 2005-11-07 2008-12-10 沃泰克斯药物股份有限公司 作为回旋酶抑制剂的苯并咪唑衍生物

Also Published As

Publication number Publication date
AU2004261545A1 (en) 2005-02-10
EP1592686A1 (de) 2005-11-09
AR042956A1 (es) 2005-07-13
ATE435859T1 (de) 2009-07-15
HK1087699A1 (en) 2006-10-20
TWI334416B (en) 2010-12-11
TW200503708A (en) 2005-02-01
CN1745077A (zh) 2006-03-08
ZA200505773B (en) 2006-09-27
JP2006528677A (ja) 2006-12-21
KR20060056270A (ko) 2006-05-24
RU2350612C2 (ru) 2009-03-27
WO2005012292A1 (en) 2005-02-10
US20090176771A1 (en) 2009-07-09
RU2005127328A (ru) 2006-02-10
JP2011046745A (ja) 2011-03-10
US7495014B2 (en) 2009-02-24
MXPA05008126A (es) 2006-03-30
SI1592686T1 (sl) 2009-12-31
JP4691033B2 (ja) 2011-06-01
CN100393714C (zh) 2008-06-11
US20130023525A1 (en) 2013-01-24
AU2004261545B2 (en) 2010-06-24
PT1592686E (pt) 2009-08-25
DK1592686T3 (da) 2009-10-19
CY1109385T1 (el) 2014-07-02
NO20053845L (no) 2005-08-16
CA2513463C (en) 2012-07-10
NZ541885A (en) 2009-01-31
MY139124A (en) 2009-08-28
US8188095B2 (en) 2012-05-29
EP1592686B1 (de) 2009-07-08
ES2327642T3 (es) 2009-11-02
CA2513463A1 (en) 2005-02-10
US20040235886A1 (en) 2004-11-25
IL169720A (en) 2011-08-31

Similar Documents

Publication Publication Date Title
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
CY2018009I2 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
DE60326611D1 (de) N und dergleichen
DE602004020474D1 (de) Vegf-traps und deren therapeutische anwendungen
DE60310339D1 (de) Querträger und Herstellungsverfahren
DE60324888D1 (de) und Herstellungsverfahren
DE60327611D1 (de) Gesichertes Mehrfachsenden
DE60319810D1 (de) Anschwemmfiltermedien und herstellungs- und verwendungsverfahren
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
NL1025404A1 (nl) Pyrazolo-triazine verbindingen en gebruik daarvan.
DE60328206D1 (de) Scheibenwaschanlagendüse und scheibenwaschanlage
DE60310542D1 (de) Kühlende zusammensetzungen und deren verwendungen
DE602004019294D1 (de) Tetrahydronaphthalin- und harnstoffderivate
DE602004030044D1 (de) Bacillus thuringiensis und deren verwendungen
DE60316588D1 (de) Neue lactame und deren verwendungen
DK1675852T3 (da) Heterocykliske 7-amino-alkylidenyl-quinoloner og -naphthyridoner
DE60330269D1 (de) Piperazinyl- und diazapanylbenzamide und-benzothioamide
ATE512148T1 (de) Pyrazolo- und imidazopyrimidinderivate
DE502004000891D1 (de) Organosilylfunktionalisierte partikel und deren herstellung
ATE476500T1 (de) Neue phospholipasen und deren verwendungen
ATE371653T1 (de) Benzoxazinderivate und deren verwendungen
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
DE10338270B4 (de) Variator und Variatoranordnung
DE60336025D1 (de) Kollimator und bestrahler
DE60323517D1 (de) Hybridisierungsnachweisverfahren und bioassay-vorr

Legal Events

Date Code Title Description
8364 No opposition during term of opposition